摘要
目的 探讨原发性肝癌患者实施C-反应蛋白、肿瘤标志物联合检测的临床诊断价值。方法 观察组选择2020年6月—2021年6月山东国欣颐养集团滕南医院收治的原发性肝癌患者60例,对照组选择同期本院诊治的肝硬化患者60例,分别进行C-反应蛋白、肿瘤标志物(CEA、CA125、SF、AFP)检测,记录对比两组患者诊断结果,统计观察组患者单一肿瘤标志物与联合检测阳性率差异。结果 观察组患者CEA、CA125、SF、AFP及CRP检测结果均明显高于对照组,差异有统计学意义(P<0.05)。观察组患者联合检测阳性率(91.67%)明显高于单一肿瘤标志物检测阳性率,差异有统计学意义(χ^(2)=27.222、16.030、19.703、11.571、29.128,P<0.05)。结论 临床可通过肿瘤标志物联合C-反应蛋白检测方式用于鉴别诊断原发性肝癌疾病,检出率、准确率高。
Objective To investigate the clinical diagnostic value of implementing the combined C-reactive protein and tumor marker test in primary liver cancer patients. Methods The observation group selected 60 patients with primary liver cancer admitted to Tengnan Hospital of Shandong Guoxin Nursing Group from June 2020 to June 2021, and the control group selected 60 patients with cirrhosis treated in the hospital during the same period. C-reactive protein and tumor markers(CEA, CA125, SF, AFP) were tested separately, and the diagnostic results of the two groups were recorded and compared, and the differences in the positive rates of single tumor markers, and combined tests of the patients in the observation group were counted. Results The analysis showed that the results of CEA, CA125, SF, AFP and CRP in the observation group were significantly higher than those in the control group, the difference was statistically significant(P<0.05). The positive rate of combined test was 91.67% significantly higher than the positive rate of single tumor marker test in the observation group patients, the difference was statistically significant(χ^(2)=27.222,16.030, 19.703, 11.571, 29.128, P<0.05). Conclusion Clinical use of tumor markers combined with C-reactive protein test for differential diagnosis of primary hepatocellular carcinoma disease with high detection rate and accuracy.
作者
赵桂敏
ZHAO Guimin(Department of Laboratory,Tengnan Hospital,Shandong Guoxin Yiyang Group,Jining,Shandong Province,277600 China)
出处
《系统医学》
2022年第21期54-57,共4页
Systems Medicine
